Why Covid-19 vaccine rollout falls short of past global campaigns. Decades-old successes benefited from more trust in science, less political polarization, less complicated procedures. My piece via @WSJ wsj.com/articles/why-c…
NYC vaccinated 6m people in less than a month in 1947, Yugoslavia jabbed *18m in three weeks* in 1972, The Netherlands was a global vax leader with Swine Flu in 2009. Why does Covid-19 vaccination fall short of past achievements? wsj.com/articles/why-c…
Vax scarcity is a problem, but so is fading trust in public institutions and science, an underfunded healthcare infrastructure, a less capable government, the rise of vaccine skepticism and even political polarization. wsj.com/articles/why-c…
“I think the credibility of governments and the population’s trust in them has gone significantly down…and as a consequence the population doesn’t just line up and agree to be vaccinated,” said Moncef Slaoui, the mastermind behind Operation Warp Speed wsj.com/articles/why-c…
Dosing regimens, rigidly based on vaccine trials, and inflexible prioritization schedules have added complexity to the current rollouts. @c_drosten said this week that "German perfectionism" appeared to stand in the way of efficient mass vaccination wsj.com/articles/why-c…
“Second doses were often delayed in the past,” said Stanley Plotkin, who developed a number of vaccines, including the shot against rubella, one of the most successful in history. In some instances, such delays actually boosted recipients’ immune responses wsj.com/articles/why-c…
Rollouts have been particularly slow in the European Union. Despite a shortage of vaccines, millions of doses are languishing in storage due to logistical bottlenecks & reluctance by to take a shot that has occasionally caused strong reactions wsj.com/articles/why-c…
“Back then, we didn’t have people questioning advice from medical doctors, but now we have this postmodern belief that medical authority needs to be questioned, that one needs to seek information on the internet instead of lining up to take the vaccine” wsj.com/articles/why-c…
The U.S., Europe, the former Soviet Union and China routinely worked hand-in-hand to combat diseases in the past —a feature lacking in today’s pandemic that has exposed deep rivalries between blocs and even between friendly nations wsj.com/articles/why-c…
Today, Western governments and some of the scientific establishment have expressed skepticism about the Russian and the Chinese Covid-19 shots. “It’s just silly to marry political ideology with public health interventions," @EpiRen said. wsj.com/articles/why-c…
Vaccine policy often disregarded geopolitics - in the past. In 1960, the Soviets used the groundbreaking oral polio vaccine developed by Albert Sabin, an American scientist, and the US then adopted the same medicine after it was trialed in the USSR wsj.com/articles/why-c…
Anti-vax campaigns are as old as vaccines, but they've never been so successful. German antivaxxer Immanuel Kant wrote smallpox inoculation could inject “bestial brutality;” his Catholic contemporaries feared that vaccination would spread Protestantism wsj.com/articles/why-c…
Today’s response to the coronavirus pandemic has suffered from polarization and incoherent messaging, as exemplified in the U.S. by the contradictory statements last year by President Trump and Dr. Fauci, the White House medical adviser wsj.com/articles/why-c…
This column about Germany’s struggle with vaccination argues that an outdated administration finds it easier to perpetuate a lockdown than to digitise medical agencies tagesspiegel.de/meinung/verkru…
Many people can’t wait to get a Covid-19 vaccine. But people in Europe are balking at taking one developed by @AstraZeneca - after the EU pressured the company to supply more vaccines. With @margheritamvs @NBisserbe @WSJ wsj.com/articles/these…
Health-worker unions say thousands of their members refuse to take one of the three Covid-19 vaccines available in the region because of concerns over efficacy and reports of side effects, the latest setback for the EU’s slow rollout wsj.com/articles/these…
After demanding that @AstraZeneca deliver more doses to the bloc, some EU leaders criticized the vaccine. French President Emmanuel Macron said last month that the shot was “quasi-ineffective” for people over 65 wsj.com/articles/these…
A majority of foreign-born Germans and their offspring now support center-right parties, a development showing how decades of immigration into Europe has transformed the continent’s demographics and is reshaping politics in unexpected ways. My @WSJ report wsj.com/articles/immig…
Germans with foreign roots are increasingly voting for the center-right, providing a new pool of voters for Merkel's conservatives as the country’s social fabric becomes increasingly diverse & traditional political allegiances dissolve with integration wsj.com/articles/immig…
“We are seeing a process of normalization,” said Viola Neu, the author of the study. As migrants become economically & culturally more integrated, get naturalized & gain the right to vote, they tend to shift support from the center-left to the center-right wsj.com/articles/immig…
Some facts on EU vaccine procurement: 1. The EU only ordered 200m doses from @BioNTech_Group & @pfizer on *November 11,* when it was already behind in the queue (the US ordered on July 22). The EU *refused* an offer to order 500m doses.
2. Despite the BioNTech/Pfizer jab winning the global race, the EU stuck to 200m. On November 17 however it ordered 400m doses from CureVac, German firm that hadn't even started Phase3 trial. Only on *December 29* did the EU order additional 100m, again trailing the US
3. Data indicating that BioNTech/Pfizer were ahead of the pack emerged already in July. On *October 6* the EU regulator EMA started a rolling review based on extremely promising late-stage trial data, which was obviously available to EU officials wsj.com/articles/germa…
Big scoop: health ministers in EU’s pharma powers Germany,France,Italy & Netherlands joined forces to obtain vaccines for the bloc (kinda nascent EU Op Warpspeed) but their leaders forced them to abdicate responsibility to the Commission, which then failed to get enough doses 1/3
This is the letter sent by the healthcare minister to the Commission, drafted in slightly apologetic tone, asking the EU executive to take over vaccine procurement. Result: the EU, pop 450m, is now stuck with mere 200m BioNTech-Pfizer and 80m Moderna jabs by the autumn (at best).
Meanwhile, the new coronavirus variant that has spread from Britain could make obtaining herd immunity more difficult: as many as 80% of the population might need to be immunised to halt the pandemic wsj.com/articles/covid…
The U.S., Canada and U.K. have started vaccinating, but the region where the Pfizer-BioNTech shot was developed is still waiting for it. Europeans are becoming unsettled with the wait as pressure grows on regulators to act fast. With @drewhinshaw wsj.com/articles/europ…
The EU’s chief drug regulator EMA is coming under pressure from some governments to authorize a Covid-19 vaccine designed and produced on EU soil, as the continent struggles to contain a deadly wave of cases ahead of Christmas wsj.com/articles/europ…
At an EU summit last week, at least three heads of government complained that it was becoming politically untenable to explain to their citizens why the U.S. and Canada were administering a Europe-made vaccine ahead of the EU wsj.com/articles/europ…
The Swedish #Covid-19 experiment is over. After a severe second #coronavirus wave - which authorities said won’t happen - the government imposed some mandatory restrictions to curb hospitalisations and deaths. My report via @WSJ wsj.com/articles/long-…
After a surge in Covid-19 infections led to rising hospitalizations and deaths, Sweden has abandoned its attempt—unique among Western nations—to combat the pandemic through voluntary measures alone @WSJwsj.com/articles/long-…
With total Covid-19-related deaths reaching almost 700 per million inhabitants, infections growing exponen-tially and hospital wards filling up, the government had to shift wsj.com/articles/long-…